| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10072204 | American Journal of Ophthalmology | 2005 | 8 Pages |
Abstract
The risk of second-eye retiniti is substantial in patients with unilateral CMV retinitis but appears to be reduced by anti-CMV therapy and by HAART-induced immune recovery. Patients are at highest risk when CD4+ T cell counts are very low and in the months immediately after CMV retinitis diagnosis.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
John H. MD, PhD, Douglas A. MD, MBA, Laura A. ScM, James P. MD, Sheila K. PhD,